Memantine in the treatment of binge eating disorder: An open‐label, prospective trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To assess preliminarily the efficacy of memantine in binge eating disorder. Method: This was an open‐label, 12‐week, flexible‐dose (5–20 mg/day) trial of memantine in binge eating disorder. The primary outcome was frequency of binge days. Secondary outcomes included frequency of binge episodes, body‐mass index (BMI), weight, Clinical Global Impressions Severity (CGI‐S), Three Factor Eating Questionnaire (TFEQ), Montgomery–Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM‐A), and Sheehan Disability Scale (SDS). Longitudinal random regression analysis was performed for frequency of binge days and episodes, BMI, weight, and CGI‐S; analysis of baseline to endpoint change was performed for all outcomes. Results: Sixteen individuals received memantine; 15 completed at least one postbaseline evaluation, 9 completed the study. Mean dose at endpoint was 18.3 mg/day. Memantine was associated with significant reductions in frequency of binge days and episodes, severity of illness (p < .001 for both analyses), disinhibition on the TFEQ (p = .015), and disability on the SDS (p < .05 for three subscales). There was no significant change in BMI, weight, MADRS, HAM‐A, and TFEQ cognitive restraint and hunger. Conclusion: In this open‐label trial, memantine was well tolerated and effective in reducing binge eating, severity of illness, and disability, but had little effect on BMI and weight. © 2008 by Wiley Periodicals, Inc. Int J Eat Disord 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Self-citationMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987
McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484
Self-citationROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01089-0 · Cited by 261
Self-citationROSENBERG, D. R., MIRZA, Y., RUSSELL, A., TANG, J., SMITH, J. M., BANERJEE, S. P., BHANDARI, R., ROSE, M., IVEY, J., BOYD, C., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000132812.44664.2d · Cited by 246
Grilo, C. M., & Masheb, R. M. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.11.010 · Cited by 199
Psychological and dietary treatments of binge eating disorder: Conceptual implications
Wonderlich, S. A., de Zwaan, M., Mitchell, J. E., Peterson, C., & Crow, S. (2003) · International Journal of Eating Disorders · doi:10.1002/eat.10206 · Cited by 81
Cited by
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
Pathological overeating: emerging evidence for a compulsivity construct
Moore, C. F., Sabino, V., Koob, G. F., & Cottone, P. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.269 · Cited by 126
“Memantine (an N-methyl-Daspartate glutamate receptor (NMDAR) uncompetitive antagonist) was found to reduce binge eating as well as ‘disinhibition’ of eating behaviors (Brennan et al, 2008).”
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
“Although they did not lose weight as a group, weight loss was seen in four patients who had a remission of binge eating.(178) Sodium oxybate, the sodium salt of gammahydroxybutyrate, is a Schedule III drug marketed for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.”
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Metadata
- Authors
- Brennan, B. P., Roberts, J. L., Fogarty, K. V., Reynolds, K. A., Jonas, J. M., & Hudson, J. I.
- Venue
- International Journal of Eating Disorders
- Publisher
- Wiley
- Published
- 2008-04-23
- Volume
- 41
- Issue
- 6
- Pages
- 520-526
- ISSN
- 0276-3478 (ISSN-L)
- 1098-108X
- OpenAlex
- W2059796546
- Cited by
- 64
- References
- 10
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memantine in the treatment of binge eating disorder: An open‐label, prospective trial. https://app.cochat.ai/papers/10.1002/eat.20541
- The paper
- Brennan, B. P., Roberts, J. L., Fogarty, K. V., Reynolds, K. A., Jonas, J. M., & Hudson, J. I. (2008). Memantine in the treatment of binge eating disorder: An open‐label, prospective trial. International Journal of Eating Disorders. https://doi.org/10.1002/eat.20541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.